Post-stroke movement disorders: Clinical manifestations and pharmacological management

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 254-262

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b   Labate, Angelo ^b   Malferrari, Giovanni ^c   Palleria, Caterina ^b   de Sarro, Giovambattista ^b  

^a Annunziata Hospital   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Dopamine; GABA; Hyperkinetic movements disorders; Hypokinetic movements disorders; Movement disorders; Post stroke; Post stroke recovery

Indexed keywords

4 AMINOBUTYRIC ACID; ACETAZOLAMIDE; BACLOFEN; BOTULINUM TOXIN; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FLUPHENAZINE; GLUTAMIC ACID; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIRACETAM; PRIMIDONE; PROPRANOLOL; QUETIAPINE; RESERPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TOPIRAMATE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID;

BASAL GANGLION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHOREA; CHOREA MINOR; CLINICAL PHARMACOLOGY; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; GABAERGIC SYSTEM; HEMIBALLISM; HEMICHOREA; HUMAN; HYPOTENSION; MEDLINE; MOTOR CORTEX; MOTOR DYSFUNCTION; MYOCLONUS; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; POST STROKE MOVEMENT DISORDER; REVIEW; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

EID: 84867570427     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217341     Document Type: Review

References (100)

1. Ghika, J.; Bogousslavsky; J. Abnormal movements. In, Bogousslavsky, J; Caplan, L; eds. Stroke Syndromes; 2nd edition. Cambridge, Cambridge University Press; 2001; pp. 162-181.
2. Handley, A.; Medcalf, P.; Hellier, K.; Dutta, D. Movement disorders after stroke. Age Ageing, 2009, 38, 260-266.
3. Chuang, C.; Fahn, S.; Frucht, S. J. The natural history and treatment of acquired hemidystonia, report of 33 cases and review of the literature. J. Neurol. Neurosurg. Psychiatry, 2002, 72, 59-67.
4. Fahn, S. Concept and classification of dystonia. In, Fahn, S; Marsden, C. D.; Calne, D. B.; eds. Advances in Neurology; Dystonia 2. New York, Raven Press; 1988, p. 58.
5. Krystkowiak, P.; Martinat, P.; Defebvre, L.; Pruvo, J. P.; Leys, D.; Destée, A. Dystonia after striatopallidal and thalamic stroke, clinicoradiological correlations and pathophysiological mechanisms. J. Neurol. Neurosurg. Psychiatry, 1998, 65, 703-708.
6. Bhatia, K. P.; Marsden, C. D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain, 1994, 117, 859-876.
7. Kim, J. S. Delayed onset mixed involuntary movements after thalamic stroke. Clinical; radiological and pathophysiological findings. Brain, 2001, 124, 299-309.
8. Krauss, J. K.; Pohle, T.; Borremans, J. J. Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Mov. Disord., 1999, 14, 497-501.
9. Alarcon, F.; Zijlmans, J. C.; Duenas, G.; Cevallos, N. Post-stroke movement disorders, report of 56 patients. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 1568-1574.
10. Ghika-Schmid, F.; Ghika, J.; Regli, F.; Bogousslavsky, J. Hyperkinetic movement disorders during and after acute stroke, the Lausanne stroke registry. J. Neurol. Sci., 1997, 146, 109-116.
11. Lehéricy, S.; Grand, S.; Pollak, P.; Poupon, F.; Le Bas, J. F.; Limousin, P.; Jedynak, P.; Marsault, C.; Agid, Y.; Vidailhet, M. Clinical characteristics and topography of lesions in movement disorders due to thalamic lesions. Neurology, 2001, 57, 1055-1066.
12. Miwa, H.; Hatori, K.; Kondo, T.; Imai, H.; Mizuno, Y. Thalamic tremor, case reports and implications of the tremor generating mechanism. Neurology, 1996, 46, 75-79.
13. Ferbert, A.; Gerwig, M. Tremor due to stroke. Mov. Disord., 2004, 8, 179-182.
14. Zijlmans, J. C. M.; Katzenschlager, R.; Daniel, S. E.; Lees, A. J. L. The L-dopa response in vascular parkinsonism. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 545-547.
15. Tatemichi, T. K.; Young, W. L.; Prohovnik, I.; Gitelman, D. R.; Correll, J. W.; Mohr, J. P. Perfusion insufficiency in limb-shaking transient ischemic attacks. Stroke, 1990, 21, 341-347.
16. Kiernan, J. A.; ed. Barr's The Human Nervous System, an Anatomical Viewpoint; 8th edition. Philadelphia, Lipincott; Williams & Wilkins; 2005, pp. 193-222.
17. Galvan, A.; Wichmann, T. Gabaergic circuits in the basal ganglia and movemets disorders. Prog. Brain Res., 2007, 160, 287-308.
18. Lin, B.; Levy, S.; Raval, A. P.; Perez-Pinzon, M. A.; Defazio, R. A. Forebrain Ischemia Triggers GABAergic system degeneration in Substantia Nigra at Chronic Stages in Rats. Cardiovasc. Psychiatry Neurol., 2010, 2010, 506952.
19. Nagasawa, H.; Araki, T.; Kogure, K. Alteration of dopamine D1 receptor in the strionigral system of the postischemic rat brain. Neurosci. Lett., 1992, 134, 271-274.
20. Krauss, G. L.; Mathews, G. C. Similarities in mechanisms and treatments for epileptic and nonepileptic myoclonus. Epilepsy Curr., 2003, 3, 19-21.
21. Siniscalchi, A.; Gallelli, L.; De Sarro, G. B. Use of antiepileptic drugs for hyperkinetic movements disorders. Curr. Neuropharmacol., 2010, 8, 359-366.
22. Poston, K. L.; Frucht, S. J. Movement disorder emergencies. J. Neurol., 2008, 255, 2-13.
23. Bhidayasiri, R.; Truong, D. D. Chorea and related disorders. Postgrad. Med. J., 2004, 80, 527-534.
24. Crossman, A. R. Functional anatomy of movement disorders. J. Anat., 2000, 196, 519-525.
25. Jankovic, J. Treatment of hyperkinetic movements disorders. Lancet Neurol., 2009, 8, 844-856.
26. Hawley, J. S.; Weiner, W. J. Hemiballismus, Current concepts and review. Parkinsonism Relat. Disord., 2011 Sep 17.
27. Pareés, I.; Hernández-Vara, J.; Álvarez-Sabín, J. Post-stroke hemichorea, observation-based study of 15 cases. Rev. Neurol., 2010, 51, 460-464.
28. Cardoso, F.; Seppi, K.; Mair, K. J.; Wenning, G. K.; Poewe, W. Seminar on choreas. Lancet Neurol., 2006, 5, 589-602.
29. Lee, M. S.; Marsden, C. D. Movement disorders following lesions of the thalamus or subthalamic region. Mov. Disord., 1994, 9, 493-507.
30. Otto, S.; Buttner, T.; Schols, L.; Windmeier, D. T.; Przuntek, H. Head tremor due to bilateral thalamic and midbrain infarction. J. Neurol., 1995, 242, 608-611.
31. Gonzalez-Alegre, P.; Ammache, Z.; Davis, P. H.; Rodnitzky, R. L. Moyamoya-induced paroxysmal dyskinesia. Mov. Disord., 2003, 18, 1051-1056.
32. Kim J. S. Delayed onset mixed involuntary movements after thalamic stroke. Clinical; radiological and pathophysiological findings. Brain, 2001, 124, 299-309.
33. Neil, W.; Curran, S.; Wattis, J. Antipsychotic prescribing in older people. Age Ageing, 2003, 32, 475-83.
34. Dewey, R. R.; Jankovic, J. Hemiballism-hemichorea. Clinical and pharmacological findings in 21 patients. Arch. Neurol., 1989, 46, 862-867.
35. Ristic, A.; Marinkovic, J.; Dragasevic, N.; Stanisavljevic, D.; Kostic, V. Long-term prognosis of vascular hemiballismus. Stroke, 2002, 33, 2109-2111.
36. Bashir, K. Clozapine for the control of hemiballismus. Clin. Neuropharmacol., 1994, 17, 477-480.
37. Liperoti, R.; Gambassi, G.; Lapane, K. L.; Chiang, C.; Pedone, C.; Mor, V.; Bernabei, R. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J. Clin. Psychiatry, 2005, 66, 1090-1096.
38. Yulug, B.; Yildiz, A.; Hüdaoglu, O.; Kilic, E.; Cam, E.; Schäbitz, W. R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res. Bull. 2006, 71, 296-300.
39. Yulug, B.; Yildiz, A.; Güzel, O.; Kilic, E.; Schäbitz, W. R.; Kilic, E. Risperidone attenuates brain damage after focal cerebral ischemia in vivo. Brain Res. Bull. 2006, 69, 656-659.
40. Bi, X.; Yan, B.; Fang, S.; Yang, Y.; He, J.; Li, X. M.; Kong, J. Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65/p50 expression. Neurol. Res., 2009, 31, 159-166.
41. Klawans, H. L.; Moses, H.; Nausieda, P. A., Bergen, D, Weiner, W. J. Treatment and prognosis of hemiballismus. N. Engl. J. Med., 1976, 295, 1348-1350.
42. De Lorey, T. M.; Olsen, R. W. Gamma-aminobutyric acid A receptor structure and function. J. Biol. Chem., 1992, 267, 16747-16750.
43. Peña, J.; Mora, E.; Cardozo, J.; Molina, O.; Montiel, C. Comparison of the efficacy of carbamazepine; haloperidol and valproic acid in the treatment of children with Sydenham's chorea, clinical follow-up of 18 patients. Arq. Neuropsiquiatr., 2002, 60, 374-377.
44. Sethi, K. D.; Patel, B. P. Inconsistent response to divalproex sodium in hemichorea/hemiballism. Neurology, 1990, 40, 1630-1631.
45. D'Amelio, M.; Callari, G.; Gammino, M.; Saia, V.; Lupi, I.; Salami, G; Ragonase, P.; Savettieri, G. Levetiracetam in the treatment of vascular chorea, a case report. Eur. J. Clin. Pharmacol., 2005, 60, 835-836.
46. Driver-Dunckley, E.; Evidente, V. G. Hemichorea-hemiballismus may respond to topiramate. Clin. Neuropharmacol., 2005, 28, 142-144.
47. Gatto, E. M.; Uribe, R. C.; Raina, G.; Gorja, M.; Folgar, S.; Micheli, F. E. Vascular hemichorea/hemiballism and topiramate. Mov. Disord., 2004, 19, 836-838.
48. Siniscalchi, A.; Gallelli, L.; Davoli, A.; De Sarro, G. Efficacy and tolerability of topiramate in vascular generalized chorea. Ann. Pharmacother., 2007, 41, 1915.
49. Albanese, A.; Barnes, M. P.; Bathia, K. P.; Fernandez-Alvarez, G.; Filippinia, T.; Gassere, J, K, Kraussf, A, Newtong, I, Rektorh, M, Savoiardoa, J, Valls-Sole. A systematic review on the diagnosis and treatment of primary [idiopathic] dystonia and dystonia plus syndromes, report of an EFNS/MDS-ES task force. Eur. J. Neurol., 2006, 13, 433-444.
50. Netravathi, M.; Pal, P. K.; Indira Devi, B. A clinical profile of 103 patients with secondary movement disorders, correlation of etiology with phenomenology. Eur. J. Neurol., 2011 doi, 10. 1111/j. 1468-1331. 2011. 03469. x.
51. Obeso, J. A.; Gimenez-Roldán, S. Clinicopathological correlation in symptomatic dystonia. Adv. Neurol., 1988, 50, 113-122.
52. Pettigrew, L. G.; Jancovic, J. Hemidystonia, a report of 22 patients and a review of the literature. J. Neurol. Neurosurg. Psychiatry, 1985, 48, 650-657.
53. Russmann, H.; Vingerhoets, F.; Ghika, J.; Maeder, P.; Bogousslavsky, J. Acute infarction limited to the lenticular nucleus, clinical; etiologic; and topographic features. Arch. Neurol., 2003, 60, 351-355.
54. Jankovic, J.; Orman, J. Tetrabenazine therapy of dystonia; chorea; tics and other dyskinesias. Neurology, 1988, 38, 391-394.
55. Lotze, T.; Jaonkovic, J. Paroxysmal kinesigenic dyskinesias. Semin. Ped. Neurol., 2003, 10, 68-79.
56. Richter, A.; Löscher, W. Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosis. Eur. J. Pharmacol., 1999, 369, 335-338.
57. Jankovic, J.; Demirkiram, M. Classification of paroxysmal dyskinesias. In, Fahn, S.; Fructh, S. J.; Troung, D. D.; Hallett, M. Eds. Myoclonus and paroxysmal dyskinesias; advances in neurology. Lippincott Williams and Wilkins, Philadelphia; USA; 2002, 89, pp. 387-400.
58. Chung, S. J.; Im, J. H.; Lee, M. C.; Kim, J. S. Hemichorea after stroke, clinical-radiological correlation. J. Neurol., 2004, 251, 725-729.
59. Choi, S. M.; Lee, S. H.; Park, M. S.; Kim, B. C.; Kim, M. K.; Cho, K. H. Disappearance of resting tremor after thalamic stroke involving the territory of the tuberothalamic artery. Parkinsonism Relat. Disord., 2008, 14, 373-375.
60. López, D. J. M.; Rojas-Marcos, I.; Sanz, F. G.; Robledo, S. A. Frontal cortical infarction and contralateral postural and international tremor. Neurologia, 2008, 23, 62-64.
61. Micheli, F.; Cersósimo, G.; Palacios, C.; Scorticati, M. C.; Tenembaum, S.; Tripoli, J. Dystonia and tremor secondary to a pediatric thalamic stroke. Parkinsonism Relat. Disord,. 1998, 4, 119-122.
62. Gerschlager, W.; Münchau, A.; Katzenschlager, R.; Brown, P.; Rothwell, J. C.; Quinn, N.; Lees, A. J.; Bhatia, K. P. Natural history and syndromic associations of orthostatic tremor, a review of 41 patients. Mov. Disord., 2004, 19, 788-795.
63. Sawle, G. Movement Disorders in Clinical Practice. ed. Oxford, Isis Medical Media; 1999.
64. Balci, K.; Utku, U.; Cobanoglu, S. Two patients with tremor caused by cortical lesions. Eur. Neurol. 2007, 57, 36-38.
65. Connor, G. S. A double-blind placebo-controlled trial of topiramate in essential tremor. Neurology, 2002, 59, 132-134.
66. Connor, G. S.; Edwards, K.; Tarsy, D. Topiramate in essential tremor, findings from double-blind; placebo-controlled; crossover trials. Clin. Neuropharmacol., 2008, 31, 97-103.
67. Ondo, W. G.; Jankovic, J.; Connor, G. S.; Pahwa, R.; Elble, R.; Stacy, M. A.; Koller, W. C.; Schwarzman, L.; Wu, S. C.; Hulihan, J. F. Topiramate essential tremor study investigators. Topiramate in essential tremor, a double-blind; placebo-controlled trial. Neurology, 2006, 66, 672-677.
68. Siniscalchi, A.; Gallelli, L.; De Sarro, G. Combined topiramate and declorazepam therapy in a patient affected by essential tremor. Parkinsonism. Relat. Disord., 2007, 13, 129-130.
69. Shibasaki, H.; Hallett, M. Electrophysiological studies of myoclonus. Muscle Nerve, 2005, 31, 157-174.
70. Caviness, J. N.; Brown, P. Myoclonus, current concepts and recent advances. Lancet Neurol., 2004, 3, 598-607.
71. Homanics, G. E.; DeLorey, T. M.; Firestone, L. L.; Quinlan, J. J.; Handforth, A.; Harrison, N. L.; Krasowski, M. D.; Rick, C. E.; Korpi, E. R.; Mäkelä, R.; Brilliant, M. H.; Hagiwara, N.; Ferguson, C.; Snyder, K.; Olsen, R. W. Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy; cleft palate; and hypersensitive behavior. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 4143-4148.
72. Rigo, J. M.; Hans, G.; Nguyen, L.; Rocher, V.; Belachew, S.; Malgrange, B.; Leprince, P.; Moonen, G.; Selak, I.; Matagne, A.; Klitgaard, H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA and glycine-gated currents. Br. J. Pharmacol., 2002, 136, 659-672.
73. Schauer, R.; Singer, M.; Sultuari, L.; Kofler, M. Suppression of cortical mvoclonus by levetiracetam. Mov. Disord., 2002, 17, 411-415.
74. Ikeda, A.; Shibasaki, H.; Tashiro, K.; Mizuno, Y.; Kimura, J. Clinical trial of piracetam in patients with myoclonus, nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov. Disord., 1996, 11, 691-700.
75. Genton, P.; Gelisse, P. Antimyoclonic effect of levetiracetam. Epileptic Disord., 2000, 2, 209-212.
76. Elia, M. Myoclonic status in nonprogressive encephalopathies, an update. Epilepsia, 2009, 50, 41-44.
77. Woodbury, D. M.; Esplin, D. W. Neuropharmacology and neurochemistry of anticonvulsant drugs. Proc. Assoc. Res. Nerv. Merit. Dis., 1969, 37, 24-56.
78. Kulisevsky, J.; Berthier, M. L.; Avila, A.; Roig, C. Unilateral Parkinsonism and stereotyped movements following a right lenticular infarction. Mov. Disord., 1996, 11, 752-754.
79. Fenelon, G.; Houeto, J. L. Unilateral Parkinsonism following a large infarct in the territory of the lenticulostriate arteries. Mov. Disord., 1997, 12, 1086-1090.
80. Kulisevsky, J.; Avila, A.; Berthier, M. L. Bipolar affective disorder and unilateral Parkinsonism after a brainstem infarction. Mov. Disord., 1995, 10, 802.
81. Winikates, J.; Jankovic, J. Clinical correlates of vascular parkinsonism. Arch. Neurol. 1999, 56, 98-102.
82. Murrow, R. W.; Schweiger, G. D.; Kepes, J. J.; Koller, W. C. Parkinsonism due to a basal ganglia lacunar state, clinicopathological correlation. Neurology, 1990, 40, 897-900.
83. Zijlmans, J. C.; Thijssen, H. O.; Vogels, O. J.; Kremer, H. P.; Poels, P. J.; Schoonderwaldt, H, C, Merx, J. L.; van 't Hof, M. A.; Thien, T.; Horstink, M. W. MRI in patients with suspected vascular parkinsonism. Neurology, 1995, 45, 2183-2188.
84. Fitz, G. P. M.; Jankovic, J. Lower body parkinsonism, evidence for a vascular etiology. Mov. Disord., 1989, 4, 249-260.
85. Demirkiran, M.; Bozdemir, H.; Sarica, Y. Vascular parkinsonism, a distinct; heterogeneous clinical entity. Acta Neurol. Scand., 2001, 104, 63-67.
86. Siniscalchi, A.; Gallelli, L.; Mercuri, N. B.; Ferreri I. G.; De Sarro, G. B. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutr. Neurosc., 2006, 9, 11-16.
87. Yong, S. W.; Lee, K. Y.; Lee, P. H. The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease, serial transcranial Doppler studies. Parkinsonism Relat. Disord., 2010, 16, 225-227.
88. Dupuis, M. J.; Evards, F. L.; Jacquerye, P. G.; Picard, G. R.; Lermen, O. G. Disappearance of essential tremor after stroke. Mov. Disord., 2010, 25, 2884-2887.
89. Ristic, A.; Marinkovic, J.; Dragasevic, N. Long-term prognosis of vascular hemiballismus. Stroke, 2002, 33, 2109-2111.
90. Duncan, P. W.; Lai, S. M.; Keighley, J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology, 2000, 39, 835-884.
91. Cramer, S. C.; Sur, M.; Dobkin, B. H.; O'Brien, C.; Sanger, T. D.; Trojanowski, J. Q.; Rumsey, J. M.; Hicks, R.; Cameron, J.; Chen, D.; Chen, W. G.; Cohen, L. G.; deCharms, C.; Duffy, C. J.; Eden, G. F.; Fetz, E. E.; Filart, R.; Freund, M.; Grant, S. J.; Haber, S.; Kalivas, P. W.; Kolb, B.; Kramer, A. F.; Lynch, M.; Mayberg, H. S.; McQuillen, P. S.; Nitkin, R.; Pascual-Leone, A.; Reuter-Lorenz, P.; Schiff, N.; Sharma, A.; Shekim, L.; Stryker, M.; Sullivan, E. V.; Vinogradov, S. Harnessing neuroplasticity for clinical applications. Brain., 2011, 134, 1591-1609.
92. Cheatwood, J. L.; Emerick, A. J.; Kartje, G. L. Neuronal plasticity and functional recovery after ischemic stroke. Top Stroke Rehabil., 2008, 15, 42-50.
93. Dijkhuizen, R. M.; Singhal, A. B.; Mandeville, J. B. Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study. J. Neurosci., 2003, 23, 510-517.
94. Rossini, P. M.; Calautti, C.; Pauri, F.; Baron, J. C. Post-stroke plastic reorganisation in the adult brain. Lancet Neurol., 2003, 2, 493-502.
95. Di Filippo, M.; Tozzi, A.; Costa, C.; Belcastro, V.; Tantucci, M.; Picconi, B.; Calabresi, P. Plasticity and repair in the post-ischemic brain. Neuropharmacology, 2008, 55, 353-362.
96. Weiller, C.; Chollet, F.; Friston, K. J.; Wise, R. J.; Frackowiak, R. S. Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann. Neurol., 1992, 31, 463-472.
97. Weiller, C.; Ramsay, S. C.; Wise, R. J.; Friston, K. J.; Frackowiak, R. S. Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. Ann. Neurol., 1993, 33, 181-189.
98. Johansson, B. B. Regeneration and plasticity in the brain and spinal cord. J Cereb Blood Flow Metab., 2007, 27, 1417-1430.
99. Rösser, N.; Flöel, A. Pharmacological enhancement of motor recovery in subacute and chronic stroke. NeuroRehabilitation, 2008, 23, 95-103.
100. Tombari, D.; Ricciardi, M. C.; Bonaffini, N.; Pasquini, M.; Cecconi, M.; Di Piero, V.; Lenzi, G. L. Functional MRI, drugs, and poststroke recovery. Clin. Exp. Hypertens., 2006, 28, 301-307.